Jinyouli (pegfilgrastim biosimilar) / CSPC Pharma - LARVOL DELTA

Efficacy, safety, and cost-effectiveness of pegylated PEG-rhg-CSF in pediatric patients receiving high-intensity chemotherapy: results from a phase II study. (PubMed, Front Pharmacol) - "Therefore, this study investigated safety and efficacy of long-acting pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF; Jinyouli®) in children undergoing high-intensity chemotherapy...PEG-rhG-CSF exhibited superior cost-effectiveness compared to rhG-CSF. Our findings indicate that PEG-rhG-CSF is safe, efficient, and cost-effective in pediatric patients undergoing high-intensity chemotherapy, providing preliminary evidence warranting further randomized controlled trials."

Cost effectiveness • HEOR • Journal • P2 data • Febrile Neutropenia • Hematological Disorders • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Pediatrics

[VIRTUAL] Efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor in the prevention of chemotherapy-induced neutropenia in patients with breast cancer. (ASCO 2020) - "Background: To explore the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF, brand name: Jinyouli) in the prevention of neutropenia in breast cancer patients receiving adjuvant chemotherapy with EC regimen (epirubicin combined with cyclophosphamide). PEG-rhG-CSF secondary prevention can effectively reduce the incidence of neutropenia in breast cancer patients receiving adjuvant chemotherapy with EC regimen, which ensures the implementation of standard-dose chemotherapy with good safety. Research Funding: CSPC Baike(Shandong) Biopharmaceutical Co., Ltd."

Breast Cancer • Fatigue • Hematological Disorders • Neutropenia • Oncology • Pain

A randomized trial of pegylated recombinant human granulocyte-colony stimulating factor to prevent febrile neutropenia in breast cancer after chemotherapy. (ASCO 2022) - " Patients with stage I-III invasive breast cancer who were scheduled to receive 4 cycles of adjuvant chemotherapy with EC regimen (epirubicin combined with cyclophosphamide) were eligible for this multicenter, open-label, randomized trial. Patients were randomized (1:1) to receive PEG-rhG-CSF (Jinyouli) 48 hours (48h group) or 24 hours (24h group) after the end of each cycle of chemotherapy... Preliminary results suggest a similar effect of PEG-rhG-CSF administration at 48 or 24 hours after chemotherapy in primary prevention of FN in breast cancer patients receiving EC chemotherapy regimen. Recruitment is ongoing and updated data will be presented."

Breast Cancer • Febrile Neutropenia • Hematological Disorders • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Solid Tumor

[VIRTUAL] A retrospective observational study on the efficacy and safety of pegylated recombinant human granulocyte-colony stimulating factor and recombinant human granulocyte-colony stimulating factor in patients with lymphoma. (ASCO 2020) - " This retrospective study included patients with newly diagnosed lymphoma who received CHOP ± R (cyclophosphamide, doxorubicin, vincristine, prednisone ± rituximab) between January 2014 to October 2018. PEG-rhG-CSF(brand name: jinyouli) was injected subcutaneously once 24-72 hours after chemotherapy as primary prevention... Compared with rhG-CSF, prophylactic use of PEG-rhG-CSF can significantly reduce the incidence of FN, grade III/IV neutropenia and chemotherapy delay in patients with lymphoma with good safety. Research Funding: CSPC Baike(Shandong) Biopharmaceutical Co., Ltd."

Observational data • Retrospective data • Fatigue • Hematological Disorders • Hematological Malignancies • Neutropenia • Oncology • Pain

Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P=N/A; N=104; Recruiting; Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Clinical • New trial • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology

[VIRTUAL] A single-center, open-label clinical study to evaluate pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte stimulating factor in pediatric patients with acute lymphoblastic leukemia. (ASCO 2020) - "Background: The aims of the study were to investigate the pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony stimulating factor(PEG-rhG-CSF) in pediatric patients with acute lymphoblastic leukemia(ALL), and compare the efficacy and safety of PEG-rhG-CSF (brand name:jinyouli) and rhG-CSF. Pediatric patients with newly diagnosed ALL who planned to use CAM (cyclophosphamide, cytarabine, 6-mercaptopurine) for chemotherapy were assigned to PEG-rhG-CSF group or rhG-CSF group... PEG-rhG-CSF had favorable efficacy in pediatric patients with ALL receiving chemotherapy, and there was no serious adverse event. Compared with rhG-CSF, PEG-rhG-CSF needed only once in each chemotherapy cycle, which is more suitable for pediatric patients. Research Funding: CSPC Baike(Shandong) Biopharmaceutical Co., Ltd."

Clinical • PK/PD data • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Neutropenia • Oncology • Pediatrics

[VIRTUAL] Efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor in the primary and secondary prevention of chemotherapy-induced neutropenia in patients with lymphoma. (ASCO 2020) - "Background: To evaluate the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF, brand name: Jinyouli) in the primary and secondary prevention of chemotherapy-induced neutropenia in patients with lymphoma... PEG-rhG-CSF can effectively reduce the incidence of FN and neutropenia with good safety in patients with lymphoma after chemotherapy. Primary prevention can significantly reduce the risk of grade IV neutropenia in all chemotherapy cycles compared with the secondary prevention. Research Funding: CSPC Baike(Shandong) Biopharmaceutical Co., Ltd."

Hematological Disorders • Hematological Malignancies • Neutropenia • Oncology • Pain

[VIRTUAL] Efficacy and safety of pegfilgrastim in prophylaxis of chemotherapy-induced neutropenia in breast cancer patients. (ASCO 2020) - "Background: The role of secondary prophylaxis with pegfilgrastim (brand name: Jinyouli) in Chinese breast cancer patients has not been fully evaluated... Prophylactic administration of pegfilgrastim is effective and safe in reducing the risk of grades 3/4 neutropenia and FN in breast cancer patients after receiving chemotherapy. Research Funding: CSPC Baike(Shandong) Biopharmaceutical Co., Ltd."

Clinical • Breast Cancer • Hematological Disorders • Neutropenia • Oncology • Pain